VOR Short Interest at a Year High as Peers Pull Away

Vor Biopharma shares closed at $19.03 on Tuesday, up 5.5% on the day but barely moved on the week, down 0.2%, while its closest clinical-stage peers posted a median gain of 6.4% over the same period. Short interest has climbed to 39.3% of the free float, the highest level recorded in the past year, and the gap between that heavy positioning and the borrow market's current looseness makes this stock one of the more unusual set-ups in biotech right now.

Short sellers have been adding steadily. Short interest has grown 2.1% over the past week and 4.1% over the past month, reaching roughly 8 million shares. What makes the positioning unusual is that borrow conditions are not tight. Availability has eased sharply, falling from around 307% a fortnight ago to 209% now, a 20% drop over the week, yet it remains well above constrained territory. Cost to borrow is just 0.52%, down 9% on the week and near a one-month low. There is no squeeze pressure visible in the lending market. Short sellers are carrying a heavy position at almost no cost. The 52-week low for availability hit 12.9%, a very different picture from today, meaning there have been periods when the borrow was genuinely difficult to source. Right now it is not.

Options positioning sits on the opposite end of sentiment from the shorts. The put/call ratio has dropped to 0.15, below its 20-day average of 0.17, and near the low end of its recent range. Call volume dominates. That divergence between a crowded short book and call-heavy options flow is the central tension on this stock right now. One side is betting on failure; the other on a catalyst that re-rates the shares higher.

William Blair initiated coverage on VOR this morning with an Outperform rating, the freshest analyst action on the stock and one that adds a bullish voice to a panel that already leans constructively. Six analysts carry Buy or equivalent ratings. The bull case rests on telitacicept, the company's dual BAFF/APRIL inhibitor. A Phase 3 interim analysis published in the NEJM in May reported a 55% placebo-adjusted reduction in a key kidney disease marker. The asset is already approved in China across three indications. The company reported $491.5 million in cash at last quarter-end, funding operations into early 2029. The bear case is concentrated: one lead asset, and a clinical or regulatory setback ends the story. Wedbush holds a Neutral rating with a $27 target, a meaningful gap below most of the panel.

The ownership register is worth noting. RA Capital Management holds a 13D activist filing, the most recent update from July 2026, with a stated position of 19.9% of the class. Three other holders, Reprogrammed Interchange LLC, ForGrowth III PA B.V., and Andrew Schwab, also sit on the 13D register, meaning this is a stock with multiple parties holding activist-level stakes. Schedule 13D/G positions are event-driven disclosures around the 5% threshold, and any of these holders could have reduced below 5% without a further filing. At the same time, FMR LLC (Fidelity) added 1.6 million shares in the most recent quarter to reach 11% of shares outstanding, and BlackRock added 2.7 million shares to clear 5.8%. RA Capital's reported institutional holding is 7.6% of shares, somewhat below the 19.9% stated in the 13D, a gap that likely reflects different calculation bases or a partial reduction since the last filing.

ABOS gained 11% on the week and 13.8% on Tuesday alone. ALXO added 26.6% over the week. EDIT rose 5.5%. The peer group is moving. VOR's flat week against that backdrop reflects either specific skepticism or profit-taking after a strong year-to-date run. Earnings are scheduled for November 6, sixteen days away. The stock has produced mixed one-day moves after prior results, ranging from a 10.5% gain in June to a 4.4% decline in August. The November print is the next hard date, and it arrives with the highest short position in at least a year still in place.